BACKGROUND: Recombination technology can be used to create live attenuated respiratory syncytial virus (RSV) vaccines that contain combinations of known attenuating mutations. METHODS: Two live attenuated, recombinantly derived RSV vaccine candidates, rA2cp248/404 Delta SH and rA2cp248/404/1030 Delta SH, were evaluated in 31 adults and in 95 children >/=6 months old. rA2cp248/404/1030 Delta SH was subsequently evaluated in 44 infants 1-2 months old. These vaccine candidates share 4 attenuating genetic elements and differ only in a missense mutation (1030) in the polymerase gene. RESULTS: Both vaccines were highly attenuated in adults and RSV-seropositive children and were well tolerated and immunogenic in RSV-seronegative children. Compared with that of rA2cp248/404 Delta SH, replication of rA2cp248/404/1030 Delta SH was restricted in RSV-seronegative children (mean peak titer, 10(4.3) vs. 10(2.5) plaque-forming units [pfu]/mL), indicating that the 1030 mutation had a potent attenuating effect. Although rA2cp248/404/1030 Delta SH was well tolerated in infants, only 44% of infants who received two 10(5.3)-pfu doses of vaccine had detectable antibody responses. However, replication after administration of the second dose was highly restricted, indicating that protective immunity was induced. At least 4 of 5 attenuating genetic elements were retained in recovered vaccine viruses. CONCLUSIONS:rA2cp248/404/1030 Delta SH is the first RSV vaccine candidate to be sufficiently attenuated in young infants. Additional studies are needed to determine whether rA2cp248/404/1030 Delta SH can induce protective immunity against wild-type RSV.
RCT Entities:
BACKGROUND: Recombination technology can be used to create live attenuated respiratory syncytial virus (RSV) vaccines that contain combinations of known attenuating mutations. METHODS: Two live attenuated, recombinantly derived RSV vaccine candidates, rA2cp248/404 Delta SH and rA2cp248/404/1030 Delta SH, were evaluated in 31 adults and in 95 children >/=6 months old. rA2cp248/404/1030 Delta SH was subsequently evaluated in 44 infants 1-2 months old. These vaccine candidates share 4 attenuating genetic elements and differ only in a missense mutation (1030) in the polymerase gene. RESULTS: Both vaccines were highly attenuated in adults and RSV-seropositive children and were well tolerated and immunogenic in RSV-seronegative children. Compared with that of rA2cp248/404 Delta SH, replication of rA2cp248/404/1030 Delta SH was restricted in RSV-seronegative children (mean peak titer, 10(4.3) vs. 10(2.5) plaque-forming units [pfu]/mL), indicating that the 1030 mutation had a potent attenuating effect. Although rA2cp248/404/1030 Delta SH was well tolerated in infants, only 44% of infants who received two 10(5.3)-pfu doses of vaccine had detectable antibody responses. However, replication after administration of the second dose was highly restricted, indicating that protective immunity was induced. At least 4 of 5 attenuating genetic elements were retained in recovered vaccine viruses. CONCLUSIONS: rA2cp248/404/1030 Delta SH is the first RSV vaccine candidate to be sufficiently attenuated in young infants. Additional studies are needed to determine whether rA2cp248/404/1030 Delta SH can induce protective immunity against wild-type RSV.
Authors: James A Berkley; Patrick Munywoki; Mwanajuma Ngama; Sidi Kazungu; John Abwao; Anne Bett; Ria Lassauniére; Tina Kresfelder; Patricia A Cane; Marietjie Venter; J Anthony G Scott; D James Nokes Journal: JAMA Date: 2010-05-26 Impact factor: 56.272
Authors: Anna R Kwilas; Mark A Yednak; Liqun Zhang; Rachael Liesman; Peter L Collins; Raymond J Pickles; Mark E Peeples Journal: J Virol Date: 2010-05-26 Impact factor: 5.103
Authors: Cyril Le Nouën; Linda G Brock; Cindy Luongo; Thomas McCarty; Lijuan Yang; Masfique Mehedi; Eckard Wimmer; Steffen Mueller; Peter L Collins; Ursula J Buchholz; Joshua M DiNapoli Journal: Proc Natl Acad Sci U S A Date: 2014-08-25 Impact factor: 11.205
Authors: Daniel Simancas-Racines; Juan Va Franco; Claudia V Guerra; Maria L Felix; Ricardo Hidalgo; Maria José Martinez-Zapata Journal: Cochrane Database Syst Rev Date: 2017-05-18
Authors: Joshua M DiNapoli; Lijuan Yang; Amorsolo Suguitan; Subbiah Elankumaran; David W Dorward; Brian R Murphy; Siba K Samal; Peter L Collins; Alexander Bukreyev Journal: J Virol Date: 2007-08-22 Impact factor: 5.103
Authors: Susan M Bueno; Pablo A González; Kelly M Cautivo; Jorge E Mora; Eduardo D Leiva; Hugo E Tobar; Glenn J Fennelly; Eliseo A Eugenin; William R Jacobs; Claudia A Riedel; Alexis M Kalergis Journal: Proc Natl Acad Sci U S A Date: 2008-12-15 Impact factor: 11.205
Authors: Peter F Wright; Anne M Deatly; Ruth A Karron; Robert B Belshe; Jian R Shi; William C Gruber; Yuwei Zhu; Valerie B Randolph Journal: J Clin Microbiol Date: 2007-05-02 Impact factor: 5.948
Authors: Anne L Hotard; Fyza Y Shaikh; Sujin Lee; Dan Yan; Michael N Teng; Richard K Plemper; James E Crowe; Martin L Moore Journal: Virology Date: 2012-10-11 Impact factor: 3.616